Could a cheaper keytruda copy work for lung cancer?
NCT ID NCT06268613
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial compares a biosimilar drug (SB27) to the standard cancer immunotherapy Keytruda in 163 people with stage II-IIIA non-small cell lung cancer who have already had surgery and chemotherapy. The main goal is to see if the body processes SB27 the same way as Keytruda. If successful, SB27 could become a more affordable alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (a biosimilar version of Keytruda)
What this could lead to
If SB27 works like Keytruda, it could offer a more affordable treatment option for early-stage lung cancer after surgery.
What could go wrong
This is an early phase 1 trial focused on drug levels in the blood, not yet on long-term outcomes. The biosimilar may not prove equally effective or safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SB Investigative Site
Gdansk, Poland
-
SB Investigative Site
Otwock, Poland
-
SB Investigative Site
Ansan, South Korea
-
SB Investigative Site
Busan, South Korea
-
SB Investigative Site
Daegu, South Korea
-
SB Investigative Site
Hwasun, South Korea
-
SB Investigative Site
Incheon, South Korea
-
SB Investigative Site
Jinju, South Korea
-
SB Investigative Site
Seongnam, South Korea
-
SB Investigative Site
Ulsan, South Korea
-
SB Investigative Site
Jaén, Jaén, Spain
-
SB Investigative Site
A Coruña, Santiago de Compostela, Spain
-
SB Investigative Site
Málaga, Spain
-
SB Investigative Site
Adana, Turkey (Türkiye)
-
SB Investigative Site
Istanbul, Turkey (Türkiye)
-
SB Investigative Site
Izmir, Turkey (Türkiye)
-
SB Investigative Site 1
Suwon, South Korea
-
SB Investigative Site 1
Ankara, Turkey (Türkiye)
-
SB Investigative Site 2
Suwon, South Korea
-
SB Investigative Site 2
Ankara, Turkey (Türkiye)
-
SB Investigative Site 3
Seoul, South Korea
-
SB Investigative Site 4
Seoul, South Korea
-
SB Investigative Site 5
Seoul, South Korea
-
SB Investigative Site 6
Seoul, South Korea